ANNEX II

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard box

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Metrobactin 250 mg tablets for dogs and cats
metronidazole

2. STATEMENT OF ACTIVE SUBSTANCES

One tablet contains:

Active substance:
Metronidazole 250 mg

3. PHARMACEUTICAL FORM

Tablets

4. PACKAGE SIZE

10 tablets
20 tablets
30 tablets
40 tablets
50 tablets
60 tablets
70 tablets
80 tablets
90 tablets
100 tablets
250 tablets
500 tablets
10 x (1 x 10) tablets
10 x (10 x 10) tablets

5. TARGET SPECIES

Dogs and cats

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

9. SPECIAL WARNINGS, IF NECESSARY

User warnings: Metronidazole may cause severe adverse reactions. See package leaflet for full user warnings

10. EXPIRY DATE

EXP: {month/year}
Shelf life of divided tablets: 3 days.

11. SPECIAL STORAGE CONDITIONS

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only.
To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Dechra Regulatory B.V.
Handelsweg 25
5531 AE Bladel
The Netherlands

16. MARKETING AUTHORISATION NUMBER(S)

Vm 50406/4016

17. MANUFACTURER'S BATCH NUMBER

Lot:

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

Aluminium-PVC/PE/PVDC **blisters**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Metrobactin 250 mg tablets
metronidazole

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Dechra Regulatory B.V.

3. EXPIRY DATE

EXP: {month/year}

4. BATCH NUMBER

Lot:

5. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only

B. PACKAGE LEAFLET

PACKAGE LEAFLET
Metrobactin 250 mg tablets for dogs and cats

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
Dechra Regulatory B.V.
Handelsweg 25
5531 AE Bladel
The Netherlands

Manufacturer responsible for batch release:
LelyPharma B.V.
Zuiveringsweg 42
8243 PZ Lelystad
The Netherlands

Genera Inc.
Svetonedeljska cesta 2
10436 Rakov Potok
Croatia

Only the site testing and releasing the batches will be mentioned on the printed leaflet.

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Metrobactin 250 mg tablets for dogs and cats
metronidazole

3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT

1 tablet contains:

Active substance:
Metronidazole 250 mg

Light brown with brown spots, round and convex flavoured tablet with a cross-shaped break line on one side.
Tablets can be divided into 2 or 4 equal parts.

4. INDICATIONS

Treatment of gastrointestinal tract infections caused by *Giardia* spp. and *Clostridium* spp. (i.e. *C. perfringens* or *C. difficile*).
Treatment of infections of the urogenital tract, oral cavity, throat and skin caused by obligate anaerobic bacteria (e.g. *Clostridium* spp.) susceptible to metronidazole.

5. CONTRAINDICATIONS

Do not use in case of hepatic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.

6. ADVERSE REACTIONS

The following adverse reactions may occur after administration of metronidazole: vomiting, hepatotoxicity and neutropenia. In very rare cases neurological signs may occur.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

Alternatively you can report via your national reporting system {national system details}.

7. TARGET SPECIES

Dogs and cats

8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

For oral use.
The recommended dose is 50 mg metronidazole per kg bodyweight per day for 5-7 days. The daily dose may be divided equally for twice daily administration (i.e. 25 mg/kg bodyweight twice daily).

To ensure administration of the correct dosage bodyweight should be determined as accurately as possible.

9. ADVICE ON CORRECT ADMINISTRATION

Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the tablet on a flat surface, with its scored side facing up and the convex (rounded) side facing the surface.



Halves: press down with your thumbs on both sides of the tablet.
Quarters: press down with your thumb in the middle of the tablet.

10. WITHDRAWAL PERIOD

Not applicable

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Shelf life of divided tablets: 3 days.
This veterinary medicinal product does not require any special storage conditions.
Do not use this veterinary medicinal product after the expiry date which is stated on the package after EXP.
The expiry date refers to the last day of that month.

12. SPECIAL WARNINGS

Special precautions for use in animals
Due to the likely variability (time, geographical) in the occurrence of metronidazole resistant bacteria, bacteriological sampling and susceptibility testing are recommended.
Whenever possible, the product should only be used based on susceptibility testing.
Official, national and regional antimicrobial policies should be taken into account when the veterinary medicinal product is used. The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals. Especially after prolonged treatment with metronidazole, neurological signs could occur'

Special precautions to be taken by the person administering the veterinary medicinal product to animals
Metronidazole has confirmed mutagenic and genotoxic properties in laboratory animals as well as in humans. Metronidazole is a confirmed carcinogen in laboratory animals and has possible carcinogenic effects in humans. However, there is inadequate evidence in humans for the carcinogenicity of metronidazole.
Metronidazole may be harmful for the unborn child.
Avoid contact with the skin or mucous membranes including hand-to-mouth contact. To avoid such contact wear impervious gloves when handling the product and/or for direct administration into the animal's mouth.
Do not allow treated dogs to lick persons immediately after intake of the medication. In case of skin contact, wash thoroughly the affected area. To avoid accidental

ingestion, particularly by a child, unused parts of the tablets should be returned to the open blister space, inserted back into the outer packaging and kept in a safe place out of the sight and reach of children. The remaining part should be used at the time of next administration.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands thoroughly after use. Metronidazole may cause hypersensitivity reactions. People with known hypersensitivity to metronidazole should avoid contact with the veterinary medicinal product.

Pregnancy and lactation
Studies in laboratory animals have shown inconsistent results with regard to teratogenic/embryotoxic effects of metronidazole. Therefore, use of this product during pregnancy is not recommended. Metronidazole is excreted in milk and use during lactation is therefore not recommended.

Interactions with other medicinal products and other forms of interaction
Metronidazole may have an inhibitory effect on the degradation of other drugs in the liver, such as phenytoin, cyclosporine and warfarin.
Cimetidine may decrease the hepatic metabolism of metronidazole resulting in increased serum concentration of metronidazole.
Phenobarbital may increase hepatic metabolism of metronidazole resulting in decreased serum concentration of metronidazole.

Overdose (symptoms, emergency procedures, antidotes)
Adverse events are more likely to occur at doses and treatment duration in excess of the recommended treatment regimen. If neurological signs occur, treatment should be discontinued and the patient should be treated symptomatically.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCTS OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

April 2022

15. OTHER INFORMATION

Aluminium - PVC/PE/PVDC blister
Cardboard box of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 25 or 50 blisters of 10 tablets
Cardboard box containing 10 boxes, each containing 1 or 10 blisters of 10 tablets

Not all pack sizes may be marketed.



Divisible tablet

Approved 07 April 2022